Viralytics Ltd
66 Hunter Street, Suite 305, Level 3
Sydney
2000
Tel: 61-2-8889-3671
Fax: 61-2-8068-6038
Website: http://www.viralytics.com/
Email: viralytics@viralytics.com
43 articles about Viralytics Ltd
-
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
-
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck’s Leading Immuno-Oncology Pipeline
2/21/2018
Merck and Viralytics Ltd today announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics...
-
Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.
-
Lepu Medical Pays $23.3M for 13% Stake in Australia's Viralytics
1/9/2018
Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.
-
Viralytics Ltd Updates CAVATAK and KEYTRUDA Combination Clinical Trials At ESMO 2016
10/10/2016
-
Viralytics Ltd Release: CAVATAK YERVOY Combination Demonstrates Promising Clinical Response Rates In Advanced Melanoma
10/10/2016
-
Viralytics Ltd Release: Positive Clinical Data From CAVATAK And YERVOY Combination Presented At The 2016 AACR Annual Meeting
4/19/2016
-
Viralytics Ltd Release: CAVATAK Increases Anti-Cancer Immune Activity In The Tumor Micro-environment
4/19/2016
-
Combinations Of Viralytics Ltd CAVATAK And Checkpoint Immunotherapy Demonstrate Anti-Cancer Activity In Preclinical Lung Cancer And Melanoma Studies
4/19/2016
-
Viralytics Ltd Release: Positive CAVATAK Clinical Data Presented At 2016 European Association Of Urology Congress
3/15/2016
-
Viralytics Ltd Completes $28 Million Placement -- SPP To Follow
12/14/2015
-
Viralytics Ltd Completes $28 Million Placement -- SPP To Follow
12/14/2015
-
Viralytics Ltd Release: Positive CAVATAKTM Clinical Data Presented At 2015 Society For Immunotherapy Of Cancer (SITC) Meeting
11/9/2015
-
Viralytics Ltd And Merck & Co., Kenilworth, New Jersey, U.S.A. To Collaborate On Combination Clinical Trial Of CAVATAK And KEYTRUDA In Lung And Bladder Cancer
11/6/2015
-
Viralytics Ltd Presents Phase 2 Melanoma Extension Cohort Data, Updated CALM Study Survival And CAVATAK/Immune Checkpoint Combination Preclinical Data At 2015 European Cancer Congress
9/28/2015
-
Viralytics Ltd Initiates Clinical Trial Of CAVATAK In Combination With PD-1 Blocker Keytruda
9/28/2015
-
Viralytics Ltd Presents CALM And STORM Clinical Trial Results At Oncolytic Virus Therapeutics Conference
6/17/2015
-
Viralytics Ltd Release; CAVATAK Presentations At Oncolytic Virus Therapeutics Conference Reinforce Potential In Bladder Cancer And Melanoma
6/16/2015